- Home
- AKA vs NMRA Comparison
AKA vs NMRA Comparison
Compare AKA & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- NMRA
- Stock Information
- Founded
- AKA 2018
- NMRA 2019
- Country
- AKA United States
- NMRA United States
- Employees
- AKA N/A
- NMRA N/A
- Industry
- AKA Catalog/Specialty Distribution
- NMRA
- Sector
- AKA Consumer Discretionary
- NMRA
- Exchange
- AKA Nasdaq
- NMRA Nasdaq
- Market Cap
- AKA 126.7M
- NMRA 112.8M
- IPO Year
- AKA 2021
- NMRA 2023
- Fundamental
- Price
- AKA $13.63
- NMRA $0.75
- Analyst Decision
- AKA Buy
- NMRA Buy
- Analyst Count
- AKA 4
- NMRA 8
- Target Price
- AKA $22.50
- NMRA $9.29
- AVG Volume (30 Days)
- AKA 18.6K
- NMRA 875.4K
- Earning Date
- AKA 05-13-2025
- NMRA 05-12-2025
- Dividend Yield
- AKA N/A
- NMRA N/A
- EPS Growth
- AKA N/A
- NMRA N/A
- EPS
- AKA N/A
- NMRA N/A
- Revenue
- AKA $586,514,000.00
- NMRA N/A
- Revenue This Year
- AKA $6.56
- NMRA N/A
- Revenue Next Year
- AKA $4.25
- NMRA N/A
- P/E Ratio
- AKA N/A
- NMRA N/A
- Revenue Growth
- AKA 8.09
- NMRA N/A
- 52 Week Low
- AKA $7.08
- NMRA $0.62
- 52 Week High
- AKA $33.73
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- AKA 67.58
- NMRA 48.00
- Support Level
- AKA $13.00
- NMRA $0.61
- Resistance Level
- AKA $15.75
- NMRA $0.74
- Average True Range (ATR)
- AKA 1.17
- NMRA 0.07
- MACD
- AKA 0.93
- NMRA 0.02
- Stochastic Oscillator
- AKA 79.09
- NMRA 67.09
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.